Epidemiology and natural history of non-alcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1017-1025

  Fazel, Yousef ^a   Koenig, Aaron B ^a   Sayiner, Mehmet ^a   Goodman, Zachary D ^a,b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Epidemiology; Fibrosis; NAFLD; NASH; Screening

Indexed keywords

BIOLOGICAL MARKER; LIVER ENZYME;

ARTICLE; ASIA; ELASTOGRAPHY; ENZYME ASSAY; EUROPE; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE;

EID: 84961226869     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.01.012     Document Type: Article

References (98)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
2. [2] Younossi, Z.M., Practical management of liver diseases. 2008, Cambridge University Press.
3. [3] Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 (2003), 1202–1219.
4. [4] Caldwell, S., Argo, C., The natural history of non-alcoholic fatty liver disease. Dig Dis 28 (2010), 162–168.
5. [5] Adams, L.A., Feldstein, A.E., Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 4 (2010), 623–635.
6. [6] Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 178 (2013), 38–45.
7. [7] Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., Dierkhising, R.A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
8. [8] Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Medicine, 11(7), 2014, 10.1371/journal.pmed.1001680.e1001680.
9. [9] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
10. [10] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
11. [11] Wanless, I.R., Lentz, J.S., Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990), 1106–1110.
12. [12] Silverman, J.F., O'Brien, K.F., Long, S., Leggett, N., Khazanie, P.G., Pories, W.J., et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85 (1990), 1349–1355.
13. [13] Machado, M., Marques-Vidal, P., Cortez-Pinto, H., Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006), 600–606.
14. [14] Angulo, P., Keach, J.C., Batts, K.P., Lindor, K.D., Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999), 1356–1362.
15. [15] Younossi, Z.M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91 (2012), 319–327.
16. [16] Lazo, M., Clark, J.M., The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28 (2008), 339–350.
17. [17] Pan, J.J., Fallon, M.B., Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 6 (2014), 274–283.
18. [18] Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
19. [19] Schneider, A.L., Lazo, M., Selvin, E., Clark, J.M., Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring) 22 (2014), 292–299.
20. [20] Loguercio, C., De Girolamo, V., de Sio, I., Tuccillo, C., Ascione, A., Baldi, F., et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 35 (2001), 568–574.
21. [21] Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58 (2013), 593–608.
22. [22] Soresi, M., Noto, D., Cefalu, A.B., Martini, S., Vigna, G.B., Fonda, M., et al. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis Society. Acta Diabetol 50 (2013), 241–249.
23. [23] Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., Bellentani, S., Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005), 44–52.
24. [24] Farrell, G.C., Wong, V.W., Chitturi, S., NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
25. [25] Amarapurkar, D.N., Hashimoto, E., Lesmana, L.A., Sollano, J.D., Chen, P.J., Goh, K.L., How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol 22 (2007), 788–793.
26. [26] Fan, J.G., Li, F., Cai, X.B., Peng, Y.D., Ao, Q.H., Gao, Y., The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 22 (2007), 663–668.
27. [27] Wang, Z., Xia, B., Ma, C., Hu, Z., Chen, X., Cao, P., Prevalence and risk factors of fatty liver disease in the Shuiguohu district of Wuhan city, central China. Postgrad Med J 83 (2007), 192–195.
28. [28] Dassanayake, A.S., Kasturiratne, A., Rajindrajith, S., Kalubowila, U., Chakrawarthi, S., De Silva, A.P., et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 24 (2009), 1284–1288.
29. [29] Pinidiyapathirage, M.J., Dassanayake, A.S., Rajindrajith, S., Kalubowila, U., Kato, N., Wickremasinghe, A.R., et al. Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. BMC Res Notes, 4, 2011, 513.
30. [30] Brunello, G., Michaud, P.-C., Sanz-de-Galdeano, A., The rise in obesity across the Atlantic: an economic perspective. (Accessed from www.oecd.org/els/41650997.pdf), 2008.
31. [31] Ogden, C.L., Carroll, M.D., Kit, B.K., Flegal, K.M., Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 307 (2012), 483–490.
32. [32] Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307 (2012), 491–497.
33. [33] Paredes, A.H., Serfaty, L., Oliveira, C.P., Chowdhury, A., Boyett, S.L., Siddiqui, M.S., et al. There is substantial phenotypic variability in lean versus obese subjects with NAFLD across the world: the Global NASH Study. Hepatology, 60(4), 2014, 593A [Abstract No:815].
34. [34] Younossi, Z.M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
35. [35] Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
36. [36] Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 (2011), 428–433 [quiz e50].
37. [37] Noureddin, M., Yates, K.P., Vaughn, I.A., Neuschwander-Tetri, B.A., Sanyal, A.J., McCullough, A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58 (2013), 1644–1654.
38. [38] Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
39. [39] Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
40. [40] Bedogni, G., Miglioli, L., Masutti, F., Castiglione, A., Croce, L.S., Tiribelli, C., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46 (2007), 1387–1391.
41. [41] Musso, G., Gambino, R., Cassader, M., Pagano, G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
42. [42] Stefan, N., Kantartzis, K., Haring, H.U., Causes and metabolic consequences of fatty liver. Endocr Rev 29 (2008), 939–960.
43. [43] Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005), 183–190.
44. [44] Younossi, Z.M., Otgonsuren, M., Venkatesan, C., Mishra, A., In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 62 (2013), 352–360.
45. [45] Dongiovanni, P., Anstee, Q.M., Valenti, L., Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 19 (2013), 5219–5238.
46. [46] Falck-Ytter, Y., Younossi, Z.M., Marchesini, G., McCullough, A.J., Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21 (2001), 17–26.
47. [47] Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 (2009), 1224–1229 [9 e1–2].
48. [48] Younossi, Z.M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53 (2011), 1874–1882.
49. [49] Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
50. [50] Reddy, S.K., Steel, J.L., Chen, H.W., DeMateo, D.J., Cardinal, J., Behari, J., et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 55 (2012), 1809–1819.
51. [51] Musso, G., Cassader, M., Olivetti, C., Rosina, F., Carbone, G., Gambino, R., Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 14 (2013), 417–431.
52. [52] Paredes, A.H., Torres, D.M., Harrison, S.A., Nonalcoholic fatty liver disease. Clin Liver Dis 16 (2012), 397–419.
53. [53] Karlas, T., Wiegand, J., Berg, T., Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 27 (2013), 195–208.
54. [54] Yilmaz, Y., Review article: non-alcoholic fatty liver disease and osteoporosis—clinical and molecular crosstalk. Aliment Pharmacol Ther 36 (2012), 345–352.
55. [55] Barshop, N.J., Sirlin, C.B., Schwimmer, J.B., Lavine, J.E., Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28 (2008), 13–24.
56. [56] Moore, J.B., Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 69 (2010), 211–220.
57. [57] Souza, M.R., Diniz Mde, F., Medeiros-Filho, J.E., Araujo, M.S., Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 49 (2012), 89–96.
58. [58] Oh, R.C., Hustead, T.R., Causes and evaluation of mildly elevated liver transaminase levels. Am Fam Physician 84 (2011), 1003–1008.
59. [59] Lee, J.K., Shim, J.H., Lee, H.C., Lee, S.H., Kim, K.M., Lim, Y.S., et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51 (2010), 1577–1583.
60. [60] Lazo, M., Selvin, E., Clark, J.M., Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 148 (2008), 348–352.
61. [61] Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003), 1286–1292.
62. [62] Sorrentino, P., Tarantino, G., Conca, P., Perrella, A., Terracciano, M.L., Vecchione, R., et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41 (2004), 751–757.
63. [63] Kunde, S.S., Lazenby, A.J., Clements, R.H., Abrams, G.A., Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42 (2005), 650–656.
64. [64] Gilmore, I.T., Burroughs, A., Murray-Lyon, I.M., Williams, R., Jenkins, D., Hopkins, A., Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36 (1995), 437–441.
65. [65] Ewe, K., Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26 (1981), 388–393.
66. [66] Seeff, L.B., Everson, G.T., Morgan, T.R., Curto, T.M., Lee, W.M., Ghany, M.G., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 8 (2010), 877–883.
67. [67] Behrens, G., Ferral, H., Transjugular liver biopsy. Semin Intervent Radiol 29 (2012), 111–117.
68. [68] Rinella, M.E., Loomba, R., Caldwell, S.H., Kowdley, K., Charlton, M., Tetri, B., et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 10 (2014), 219–227.
69. [69] Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Kechagias, S., Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scand J Gastroenterol 47 (2012), 108–115.
70. [70] Sanyal, A.J., Brunt, E.M., Kleiner, D.E., Kowdley, K.V., Chalasani, N., Lavine, J.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
71. [71] Neuschwander-Tetri, B.A., Clark, J.M., Bass, N.M., Van Natta, M.L., Unalp-Arida, A., Tonascia, J., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52 (2010), 913–924.
72. [72] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 [e10].
73. [73] Alkhouri, N., McCullough, A.J., Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y) 8 (2012), 661–668.
74. [74] Campos, G.M., Bambha, K., Vittinghoff, E., Rabl, C., Posselt, A.M., Ciovica, R., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47 (2008), 1916–1923.
75. [75] Myers, R.P., Pomier-Layrargues, G., Kirsch, R., Pollett, A., Duarte-Rojo, A., Wong, D., et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 55 (2012), 199–208.
76. [76] Zein, C., Edmilson, J., Schluchter, M., Feldstein, A., Zein, N., McCullough, A., NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease. Hepatology, 46, 2007, 747A.
77. [77] Barsic, N., Lerotic, I., Smircic-Duvnjak, L., Tomasic, V., Duvnjak, M., Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 18 (2012), 3945–3954.
78. [78] Feldstein, A.E., Wieckowska, A., Lopez, A.R., Liu, Y.C., Zein, N.N., McCullough, A.J., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50 (2009), 1072–1078.
79. [79] Yang, M., Xu, D., Liu, Y., Guo, X., Li, W., Guo, C., et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One, 10, 2015, e0131664.
80. [80] Kamada, Y., Ono, M., Hyogo, H., Fujii, H., Sumida, Y., Mori, K., et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology 62 (2015), 1433–1443.
81. [81] Golabi, P., Sayiner, M., Fazel, Y., Koenig, A., Henry, L., Younossi, Z.M., Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 10 (2015), 63–71.
82. [82] Rossi, E., Adams, L.A., Ching, H.L., Bulsara, M., MacQuillan, G.C., Jeffrey, G.P., High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clin Chem Lab Med 51 (2013), 1107–1114.
83. [83] Poynard, T., Ratziu, V., Charlotte, F., Messous, D., Munteanu, M., Imbert-Bismut, F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 34.
84. [84] Shimada, M., Kawahara, H., Ozaki, K., Fukura, M., Yano, H., Tsuchishima, M., et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 102 (2007), 1931–1938.
85. [85] Palekar, N.A., Naus, R., Larson, S.P., Ward, J., Harrison, S.A., Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26 (2006), 151–156.
86. [86] McPherson, S., Stewart, S.F., Henderson, E., Burt, A.D., Day, C.P., Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 1265–1269.
87. [87] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
88. [88] Chitturi, S., Farrell, G.C., Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21 (2001), 27–41.
89. [89] Younossi, Z.M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21 (2011), 431–439.
90. [90] Guha, I.N., Parkes, J., Roderick, P., Chattopadhyay, D., Cross, R., Harris, S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47 (2008), 455–460.
91. [91] Wieckowska, A., Zein, N.N., Yerian, L.M., Lopez, A.R., McCullough, A.J., Feldstein, A.E., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006), 27–33.
92. [92] Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60 (2014), 167–174.
93. [93] Yoneda, M., Fujita, K., Inamori, M., Tamano, M., Hiriishi, H., Nakajima, A., Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 56 (2007), 1330–1331.
94. [94] Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chan, H.L., Le Bail, B., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51 (2010), 454–462.
95. [95] Gaia, S., Carenzi, S., Barilli, A.L., Bugianesi, E., Smedile, A., Brunello, F., et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 54 (2011), 64–71.
96. [96] Wong, G.L., Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) 1 (2013), 19–26.
97. [97] Talwalkar, J.A., Yin, M., Fidler, J.L., Sanderson, S.O., Kamath, P.S., Ehman, R.L., Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47 (2008), 332–342.
98. [98] Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928.